Statin-associated muscle-related adverse effects: A case series of 354 patients

Pharmacotherapy

Volumn 30, Issue 6, 2010, Pages 541-553

  Cham, Stephanie ^a   Evans, Marcella A ^a   Denenberg, Julie O ^a   Golomb, Beatrice A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Drug adverse effects; Muscle; Myalgia; Myopathy; Quality of life; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE STUDY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE DISEASE; MUSCLE RELATED ADVERSE EFFECT; MUSCLE WEAKNESS; MYALGIA; OPEN ENDED QUESTIONNAIRE; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE FATIGUE; MUSCLE WEAKNESS; PAIN; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; RECURRENCE; TIME FACTORS;

EID: 77952945236     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.6.541     Document Type: Article

References (75)

1. IMS Health. U.S. top ten products by prescriptions. Available from http://wwwimshealthcom/public/structure/dispcontent/1,2779,1343-1343-144004, 00html. Accessed April 19, 2002.
2. IMS Health. Lipitor leads the way in 2003. Available from http://wwwims-globalcom/insight/news-story/0403/news-story-040316htm. Accessed May 23, 2005.
3. IMS Health. IMS global insights - IMS retail drug monitor December 2007. Available from http://wwwimshealthcom/web/content/0,3148,64576068-63872702- 70260998-83746585,00html. Accessed May 2, 2008.
4. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J 1991;104:493-495
5. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999;92:387-394
6. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585
7. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 1999;143:459-460 (Pubitemid 29166930)
8. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Does more aggressive statin therapy increase muscle and liver risk? Presented at the 55th annual meeting of the American College of Cardiology, Atlanta, GA, March 11-14, 2006.
9. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair 2005;19:259-263
10. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. Aust N Z J Med 1995;25:374-375
11. England JD, Viles A, Walsh JC, Stewart PM. Muscle side effects associated with simvastatin therapy. Med J Aust 1990;153:562-563 (Pubitemid 20387424)
12. Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation [letter]? Atherosclerosis 2000;149:225. (Pubitemid 30125996)
13. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253-260 (Pubitemid 46661859)
14. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-409
15. Cziraky MJ, Willey VJ, McKenney JM. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97:C61-8.
16. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799
17. Sinzinger H, Chehne F, Lupattelli G. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf 2002;25:877-883 (Pubitemid 35178645)
18. Sinzinger H, Lupattelli G, Chehne F, Oguogho A, Furberg CD. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 2001;26: 303-310 (Pubitemid 34205782)
19. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57: 525-528 (Pubitemid 38519660)
20. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40:163-171
21. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162 (Pubitemid 44167798)
22. Phillips PS, Haas RH. Observations from a statin myopathy clinic. Arch Intern Med 2006;166:1232-1233
23. Fisher S, Bryant SG, Kent TA, Davis JE. Patient drug attributions and postmarketing surveillance. Pharmacotherapy 1994;14:202-209 (Pubitemid 24108304)
24. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414 (Pubitemid 43228152)
25. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007;30:669-675
26. Griffin GC, Parkinson RW, Woolley BH. Report every adverse drug reaction! We're all in this together. Postgrad Med 1997;101:13-16.
27. Naranjo CC, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245 (Pubitemid 12149145)
28. Food and Drug Administration. FDA public health advisory on Crestor (rosuvastatin). Available from http://wwwfdagov/cder/drug/advisory/crestor-3- 2005htm. Accessed March 2, 2005.
29. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-107
30. Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy 2008;28:553-561
31. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD statin study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202.
32. Clark P, Lavielle P, Martinez H. Learning from pain scales: patient perspective. J Rheumatol 2003;30:1584-1588 (Pubitemid 36835461)
33. Rosier EM, Iadarola MJ, Coghill RC. Reproducibility of pain measurement and pain perception. Pain 2002;98:205-216
34. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272:619-626
35. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389
36. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
37. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630 (Pubitemid 35379733)
38. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-1622
39. Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. J Am Coll Cardiol 2004;44:1009-1010
40. Kaan A. Serious adverse event analysis: lipid-lowering therapy revisited. Therapeutics Letter 2001;42(Aug-Oct):1-2.
41. Golomb BA, Parrish J, Broadwin JA. Statins and mortality. On the Risk 2009;25:66-71.
42. IMS Health. Commonly requested therapeutic class and product Information (update February 2006). Available from http://www1imshealthcom/ims/portal/front/ articleC/0,2777,6599-18731-77056778,00html. Accessed April 17, 2009
43. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
44. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Curr Med Res Opin 1999;15:228-240 (Pubitemid 29481481)
45. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998;82:J3-10.
46. 10 deficiency. Arch Neurol 2005;62:317-320
47. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
48. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18(suppl): S137-44.
49. 10 on C2C12 myotubes: 2436. Med Sci Sports Exerc 2005;37(5 suppl):S466-7.
50. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003;370(pt 3):751-762
51. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801. (Pubitemid 34987553)
52. Matthews CE, Jurj AL, Shu XO, et al. Influence of exercise, walking, cycling, and overall nonexercise physical activity on mortality in Chinese women. Am J Epidemiol 2007;165: 1343-1350 (Pubitemid 47234317)
53. Treat-Jacobson D, Walsh ME. Treating patients with peripheral arterial disease and claudication. J Vasc Nurs 2003;21:5-14. (Pubitemid 36886659)
54. Khan S, Cleanthis M, Smout J, Flather M, Stansby G. Lifestyle modification in peripheral arterial disease. Eur J Vasc Endovasc Surg 2005;29:2-9. (Pubitemid 39618986)
55. Okumiya K, Matsubayashi K, Wada T, Kimura S, Doi Y, Ozawa T. Effects of exercise on neurobehavioral function in community-dwelling older people more than 75 years of age. J Am Geriatr Soc 1996;44:569-572 (Pubitemid 26137239)
56. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005;28:1-8. (Pubitemid 40051319)
57. Ernst E. Exercise for female osteoporosis: a systematic review of randomised clinical trials. Sports Med 1998;25:359-368 (Pubitemid 28359333)
58. Gaesser GA. Exercise for prevention and treatment of cardiovascular disease, type 2 diabetes, and metabolic syndrome. Curr Diab Rep 2007;7:14-19. (Pubitemid 46344184)
59. Church TS, Cheng YJ, Earnest CP, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care 2004;27:83-88
60. Bernstein L, Patel AV, Ursin G, et al. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst 2005;97:1671-1679
61. Hirose K, Hamajima N, Takezaki T, Miura S, Tajima K. Physical exercise reduces risk of breast cancer in Japanese women. Cancer Sci 2003;94:193-199 (Pubitemid 36575880)
62. Schnohr P, Parner J, Lange P. Joggers live longer: the Osterbro study [in Danish]. Ugeskr Laeger 2001;163:2633-2635
63. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690
64. De Vivo DC, DiMauro S. Mitochondrial defects of brain and muscle. Biol Neonate 1990;58(suppl 1):54-69.
65. Scranton RE, Cantillon C, Gagnon D, Fiore L, Gaziano JM. Occurrences of rhabdomyolysis or myositis among statin users in a Veteran Affairs population [abstract]. Circulation 2004;109:P154.
66. Golomb B, Yang E, Denenberg J, Criqui M. Statin-associated muscle adverse effects [abstract]. Circulation 2003;107: e7028-9.
67. Danish Medicines Agency. Changes of product information for Crestor (rosuvastatin) [updated 2004]. Available from http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=3546. Accessed January 15, 2005.
68. Hosein S. Warnings issued in Canada and the European Union about lipid drug. CATIE News, June 28, 2004. Available from http://www.aegis.com/ news/catie/2004/CATE-N20040602.html. Accessed January 15, 2005.
69. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004;3:547-557
70. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61.
71. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504 (Pubitemid 38477774)
72. Fisher S, Bryant SG, Kluge RM. New approaches to postmarketing surveillance. Psychopharmacology (Berl) 1986;90:347-350
73. Fisher S, Bryant SG. Postmarketing surveillance: accuracy of patient drug attribution judgments. Clin Pharmacol Ther 1990;48:102-107 (Pubitemid 20236208)
74. Fisher S, Bryant SG. Postmarketing surveillance of adverse drug reactions: patient self-monitoring. J Am Board Fam Pract 1992;5:17-25.
75. Jarernsiripornkul N, Krska J, Richards RM, Capps PA. Patient reporting of adverse drug reactions: useful information for pain management? Eur J Pain 2003;7:219-224